Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05270044
Title	Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)
Acronym	COLUMBUS-AD
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Pierre Fabre Medicament
Indications	skin melanoma
Therapies	Binimetinib + Encorafenib
Age Groups:	adult \| senior
Covered Countries	SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG